skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
12407440
Filing Dt:
03/19/2009
Publication #:
Pub Dt:
08/13/2009
Inventors:
Tong Zhang, Charles L. Sentman
Title:
Chimeric NK receptor and methods for treating cancer
Assignment: 1
Reel/Frame:
022570/0618Recorded: 04/21/2009Pages: 6
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
04/15/2009
Exec Dt:
04/15/2009
Assignee:
11 ROPE FERRY ROAD, SUITE 6210
TECHNOLOGY TRANSFER OFFICE
HANOVER, NEW HAMPSHIRE 03755-1404
Correspondent:
LICATA & TYRRELL P.C.
66 E. MAIN STREET
MARLTON, NJ 08053
Assignment: 2
Reel/Frame:
023382/0564Recorded: 10/16/2009Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
09/09/2009
Assignee:
NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
6705 ROCKLEDGE DRIVE, SUITE 310, MSC 7980
BETHESDA, MARYLAND 20892-7980
Correspondent:
DIRECTOR, DEITR
NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
MSC 7980
BETHESDA, MD 20892-7980
Assignment: 3
Reel/Frame:
044919/0760Recorded: 12/20/2017Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
12/18/2017
Assignee:
NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
6705 ROCKLEDGE DRIVE, SUITE 310, MSC 7980
BETHESDA, MARYLAND 20892-7980
Correspondent:
DIRECTOR, DEITR
NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
MSC 7980
BETHESDA, MD 20892-7980

Search Results as of: 05/17/2024 07:54 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT